Benitec Biopharma to Participate in a Fireside Chat at the 35th Annual Piper Sandler Healthcare Conference
November 17 2023 - 8:00AM
Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a
clinical-stage, gene therapy-focused, biotechnology company
developing novel genetic medicines based on its proprietary
DNA-directed RNA interference (“ddRNAi”) platform, today announced
that Jerel A. Banks, M.D., Ph.D., Executive Chairman and Chief
Executive Officer of Benitec, will participate in a Fireside Chat
at the 35th Annual Piper Sandler Healthcare Conference on Thursday,
November 30th, 2023 at 10:00 am ET.
A live webcast of the presentation will be
accessible from the Investor section of Benitec’s website at
ir.benitec.com. An archived version of the webcast will be
available in the Events section of the Investors page of Benitec’s
website for 90 days following the event.
About Benitec Biopharma
Inc.
Benitec Biopharma Inc. (“Benitec” or the
“Company”) is a clinical-stage biotechnology company focused on the
advancement of novel genetic medicines with headquarters in
Hayward, California. The proprietary DNA-directed RNA interference
“Silence and Replace” platform combines RNA interference, or RNAi,
with gene therapy to create medicines that simultaneously
facilitate sustained silencing of disease-causing genes and
concomitant delivery of wildtype replacement genes following a
single administration of the therapeutic construct. The Company is
developing Silence and Replace-based therapeutics for chronic and
life-threatening human conditions including Oculopharyngeal
Muscular Dystrophy (OPMD). A comprehensive overview of the Company
can be found on Benitec’s website at www.benitec.com.
Investor Relations Contact:
William WindhamVP, Solebury Strategic
CommunicationsPhone: 646-378-2946Email:
wwindham@soleburystrat.com
Benitec Biopharma (NASDAQ:BNTC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Benitec Biopharma (NASDAQ:BNTC)
Historical Stock Chart
From Sep 2023 to Sep 2024